LU92736I2 - Ospémifène dans toutes les formes protégées par lebrevet de base - Google Patents

Ospémifène dans toutes les formes protégées par lebrevet de base Download PDF

Info

Publication number
LU92736I2
LU92736I2 LU92736C LU92736C LU92736I2 LU 92736 I2 LU92736 I2 LU 92736I2 LU 92736 C LU92736 C LU 92736C LU 92736 C LU92736 C LU 92736C LU 92736 I2 LU92736 I2 LU 92736I2
Authority
LU
Luxembourg
Prior art keywords
ospemifene
baseline
forms protected
protected
forms
Prior art date
Application number
LU92736C
Other languages
English (en)
French (fr)
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92736(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of LU92736I2 publication Critical patent/LU92736I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
LU92736C 2004-02-13 2015-06-10 Ospémifène dans toutes les formes protégées par lebrevet de base LU92736I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene

Publications (1)

Publication Number Publication Date
LU92736I2 true LU92736I2 (fr) 2015-08-10

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92736C LU92736I2 (fr) 2004-02-13 2015-06-10 Ospémifène dans toutes les formes protégées par lebrevet de base

Country Status (22)

Country Link
US (5) US8236861B2 (pt)
EP (1) EP1713458B1 (pt)
JP (2) JP5577011B2 (pt)
CN (1) CN1925847A (pt)
AT (1) ATE387910T1 (pt)
AU (1) AU2005211958B2 (pt)
BE (1) BE2015C033I2 (pt)
BR (1) BRPI0507661A (pt)
CA (1) CA2556089C (pt)
CY (2) CY1111014T1 (pt)
DE (1) DE602005005165T2 (pt)
DK (1) DK1713458T5 (pt)
ES (1) ES2302177T3 (pt)
HU (1) HUS1500030I1 (pt)
LT (1) LTC1713458I2 (pt)
LU (1) LU92736I2 (pt)
MX (1) MXPA06009274A (pt)
NO (2) NO337656B1 (pt)
PL (1) PL1713458T3 (pt)
PT (1) PT1713458E (pt)
RU (1) RU2385716C2 (pt)
WO (1) WO2005077350A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
ES2392344T3 (es) 2004-05-04 2012-12-07 Hormos Medical Ltd. Formulaciones orales líquidas de ospemifeno
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
CA2628964A1 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
MX2008006885A (es) * 2005-11-28 2008-10-20 Gtx Inc Agentes de enlace de receptores nucleares.
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EP2121553B1 (en) * 2007-02-14 2012-06-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
JP6174156B2 (ja) 2012-10-19 2017-08-02 フェルミオン オサケ ユキチュア オスペミフェンの製造方法
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
HRP20231447T1 (hr) 2018-05-11 2024-03-01 Xenon Pharmaceuticals Inc. Postupci za povećanje bioraspoloživosti i izloženosti naponski upravljanog otvarača kalijevih kanala

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
EP1102755B1 (en) * 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
US6219674B1 (en) * 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
WO2002069254A2 (en) 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
EP1509215B1 (en) 2002-06-06 2006-11-02 Hormos Medical Ltd. Treatment or prevention of urogenital atrophy and its symptoms in women
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) * 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency

Also Published As

Publication number Publication date
BRPI0507661A (pt) 2007-07-17
JP5577011B2 (ja) 2014-08-20
ES2302177T3 (es) 2008-07-01
WO2005077350A1 (en) 2005-08-25
US8772353B2 (en) 2014-07-08
CA2556089C (en) 2013-04-02
CY2015027I1 (el) 2016-04-13
CA2556089A1 (en) 2005-08-25
DE602005005165D1 (de) 2008-04-17
EP1713458B1 (en) 2008-03-05
DE602005005165T2 (de) 2009-04-30
HUS1500030I1 (hu) 2015-08-28
US8236861B2 (en) 2012-08-07
LTPA2015023I1 (lt) 2015-08-25
CN1925847A (zh) 2007-03-07
NO20063960L (no) 2006-11-03
AU2005211958A1 (en) 2005-08-25
US9855224B2 (en) 2018-01-02
US9241915B2 (en) 2016-01-26
AU2005211958B2 (en) 2010-11-25
RU2385716C2 (ru) 2010-04-10
PL1713458T3 (pl) 2008-08-29
ATE387910T1 (de) 2008-03-15
US20050182143A1 (en) 2005-08-18
NO337656B1 (no) 2016-05-23
US8470890B2 (en) 2013-06-25
CY2015027I2 (el) 2016-04-13
RU2006132719A (ru) 2008-03-20
LTC1713458I2 (lt) 2017-06-26
DK1713458T3 (da) 2008-07-07
NO20151603L (no) 2006-11-03
US20140303259A1 (en) 2014-10-09
US20160101065A1 (en) 2016-04-14
US20120270952A1 (en) 2012-10-25
DK1713458T5 (da) 2008-09-29
CY1111014T1 (el) 2015-06-11
BE2015C033I2 (pt) 2024-08-08
US20130324614A1 (en) 2013-12-05
JP6023119B2 (ja) 2016-11-09
JP2007522190A (ja) 2007-08-09
MXPA06009274A (es) 2007-04-16
PT1713458E (pt) 2008-05-07
NO339190B1 (no) 2016-11-14
JP2014141533A (ja) 2014-08-07
EP1713458A1 (en) 2006-10-25

Similar Documents

Publication Publication Date Title
LU92736I2 (fr) Ospémifène dans toutes les formes protégées par lebrevet de base
ATE506054T1 (de) Feste formulierungen von ospemifen
AR051754A1 (es) Metodos para preparar compuestos de indazol
HRP20150119T1 (hr) N-supstituirani derivati glicina kao inhibitori hidroksilaze
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
WO2006069155A3 (en) Inhibitors of protein arginine methyl transferases
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
JP2009507896A5 (pt)
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
EA200801619A1 (ru) Способ улучшения фармакокинетики ингибиторов интегразы вич (варианты), набор и фармацевтическая композиция (варианты)
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
EA201100994A1 (ru) Способ получения производных бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ лечения или профилактики ретровирусных инфекций с ее помощью
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
JP2005536503A5 (pt)
EA022994B1 (ru) Способ подавления толерантности к опиоидному анальгетику
NO20082181L (no) Formuleringer av Fispemifen
DK1791537T3 (da) 3-arylthioindol-2-carboxamidderivater og analoger deraf som inhibitorer af casein-kinase
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
NO20090395L (no) Farmasoytiske preparater inneholdende monoklonale antidiotype anti-CA-125-antistoff og aluminiumderivater
WO2008099781A1 (ja) アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
EA200901085A1 (ru) Производные циклогексиламида арилкарбоновой кислоты
BRPI0510465A (pt) formulação de droga oral semi-sólida ou lìquida
RU2007115741A (ru) Производные 4,6-диметил-2,3-дигидро-1н-пиразоло[4,3-с]пиридин-3-онов и эфиры 2,6-диметил-4-фенил-гидразиноникотиновых кислот в качестве промежуточных продуктов для их синтеза, обладающие антидепрессантной и анксиолитической активностью
DE602005016711D1 (de) Isoxazolsäure-derivat zur linderung neuropathischer schmerzen